{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:47:56Z","timestamp":1787237276805,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007974-22"],"award-info":[{"award-number":["T32HL007974-22"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.transci.2025.104081","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T19:30:32Z","timestamp":1738006232000},"page":"104081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review"],"prefix":"10.1016","volume":"64","author":[{"given":"Jeremy W.","family":"Jacobs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Binns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Schlafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett S.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Adkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2025.104081_bib1","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.1503\/cmaj.160142","article-title":"Thrombotic microangiopathies: a general approach to diagnosis and management","volume":"189","author":"Arnold","year":"2017","journal-title":"Cmaj"},{"key":"10.1016\/j.transci.2025.104081_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjh.12303","article-title":"Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR)","volume":"161","author":"Bennett","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2025.104081_bib3","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.bbmt.2017.08.019","article-title":"Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy","volume":"23","author":"Bohl","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.transci.2025.104081_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1200\/JOP.2016.012096","article-title":"Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer","volume":"12","author":"Morton","year":"2016","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.transci.2025.104081_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice \u2013 evidence-based approach from the writing committee of the American Society for Apheresis: the ninth special issue","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2025.104081_bib6","article-title":"Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli","year":"2022","journal-title":"Front Pharm"},{"key":"10.1016\/j.transci.2025.104081_bib7","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.transci.2025.104081_bib8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1055\/s-0032-1328886","article-title":"Drug-associated thrombotic microangiopathies","volume":"38","author":"Kreuter","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2025.104081_bib9","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/bjh.19263","article-title":"Alemtuzumab-induced immune-mediated thrombotic thrombocytopenic purpura: a newly described drug-related autoimmune disease","volume":"204","author":"Bourdin","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2025.104081_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00415-021-10664-w","article-title":"Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients","volume":"269","author":"Rauma","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.transci.2025.104081_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1352458518816612","article-title":"Immune thrombocytopenia in alemtuzumab-treated MS patients: incidence, detection, and management","volume":"26","author":"Cuker","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.transci.2025.104081_bib12","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/bloodadvances.2022008968","article-title":"Severe autoimmune intravascular hemolytic anemia in patients receiving alemtuzumab for multiple sclerosis","volume":"7","author":"Sharma","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2025.104081_bib13","unstructured":"United States Food & Drug Administration. LEMTRADA\u00ae (alemtuzumab). Package insert. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103948s5182lbl.pdf\u3009. [Accessed 21 November 2024]."},{"key":"10.1016\/j.transci.2025.104081_bib14","unstructured":"European Medicines Agency. Lemtrada. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lemtrada\u3009. [Accessed 21 November 2024]."},{"key":"10.1016\/j.transci.2025.104081_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbmt.2007.08.052","article-title":"Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease","volume":"14","author":"G\u00f3mez-Almaguer","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.transci.2025.104081_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40263-016-0394-8","article-title":"Alemtuzumab use in clinical practice: recommendations from european multiple sclerosis experts","volume":"31","author":"Berger","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.transci.2025.104081_bib17","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.transci.2025.104081_bib18","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000868","article-title":"Mitigating alemtuzumab-associated autoimmunity in MS: a \"whack-a-mole\" B-cell depletion strategy","volume":"7","author":"Meltzer","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.transci.2025.104081_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/imm.12696","article-title":"Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis","volume":"150","author":"von Kutzleben","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.transci.2025.104081_bib20","unstructured":"United States Food & Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard."},{"key":"10.1016\/j.transci.2025.104081_bib21","unstructured":"United States Food & Drug Administration. FDA Adverse Event Reporting System."},{"key":"10.1016\/j.transci.2025.104081_bib22","first-page":"95A","article-title":"Thrombotic thrombocytopenic purpura (TTP) in a patient with multiple sclerosis receiving alemtuzumab","volume":"58","author":"Stoddart","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2025.104081_bib23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00062752-200109000-00004","article-title":"Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"8","author":"Medina","year":"2001","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.transci.2025.104081_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/TP.0000000000001873","article-title":"Maintenance belatacept-based immunosuppression in lung transplantation recipients who failed calcineurin inhibitors","volume":"102","author":"Iasella","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.transci.2025.104081_bib25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104081_bib26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood.V110.11.1315.1315","article-title":"Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): frequency, presenting features, and clinical outcomes","volume":"110","author":"Saste","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104081_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/cei.13208","article-title":"Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis","volume":"194","author":"Li","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.transci.2025.104081_bib28","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1185\/03007990802215315","article-title":"Analytical approaches to reporting long-term clinical trial data","volume":"24","author":"Papp","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.transci.2025.104081_bib29","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/bjh.18577","article-title":"Drug-induced thrombotic thrombocytopenic purpura: a systematic review and review of European and North American pharmacovigilance data","volume":"201","author":"Schofield","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2025.104081_bib30","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/j.ajkd.2018.09.013","article-title":"Acute thrombotic microangiopathy and cortical necrosis following administration of alemtuzumab: a case report","volume":"73","author":"Liou","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transci.2025.104081_bib31","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/ajh.27458","article-title":"The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: epidemiologic findings from a multi-center analysis of 719 disease episodes","volume":"99","author":"Jacobs","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2025.104081_bib32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bjh.18627","article-title":"Autoimmune haemolytic anaemia and immune thrombocytopenia following SARS-CoV-2 and non-SARS-CoV-2 vaccination: 32\u2009years of passive surveillance data","volume":"201","author":"Jacobs","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2025.104081_bib33","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00277-023-05136-2","article-title":"Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination","volume":"102","author":"Jacobs","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.transci.2025.104081_bib34","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.transci.2025.104081_bib35","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1016\/j.vaccine.2021.04.054","article-title":"Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the vaccine adverse event reporting system (VAERS)","volume":"39","author":"Welsh","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.transci.2025.104081_bib36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40264-017-0507-4","article-title":"Validation of new signal detection methods for web query log data compared to signal detection algorithms used with FAERS","volume":"40","author":"Colilla","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.transci.2025.104081_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2105-15-17","article-title":"Large-scale combining signals from both biomedical literature and the FDA adverse event reporting system (FAERS) to improve post-marketing drug safety signal detection","volume":"15","author":"Xu","year":"2014","journal-title":"BMC Bioinform"},{"key":"10.1016\/j.transci.2025.104081_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s13760-018-0882-3","article-title":"Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus","volume":"118","author":"Lambert","year":"2018","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.transci.2025.104081_bib39","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2025.104081_bib40","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104081_bib41","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.transci.2025.104081_bib42","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.transci.2025.104081_bib43","doi-asserted-by":"crossref","DOI":"10.2217\/cer-2022-0127","article-title":"Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA","volume":"12","author":"Araujo","year":"2023","journal-title":"J Comp Eff Res"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225000151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225000151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:35:25Z","timestamp":1777332925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050225000151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1473050225000151"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2025.104081","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2025.104081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104081"}}